Understand the source comparison
Comparison of Peptide Mechanisms in ACL Healing
BPC-157 Growth factor receptor sensitization, VEGF upregulation Days 0–14 (inflammatory resolution) Increases type I collagen gene expression 2.3× Promotes angiogenesis, increases capillary density 40–60% Animal models (rat, rabbit); limited human case series
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- BPC-157
- Growth factor receptor sensitization, VEGF upregulation
- Days 0–14 (inflammatory resolution)
- Increases type I collagen gene expression 2.3×
- Promotes angiogenesis, increases capillary density 40–60%
- Animal models (rat, rabbit); limited human case series
- TB-500
- Actin-binding, fibroblast migration, MMP-2 upregulation
- Days 3–21 (proliferative phase)
- Clears damaged collagen fragments, increases fibroblast recruitment 60%
- Minimal direct vascular effect
- Equine tendon studies; human off-label use case reports
- GHK-Cu
- Lysyl oxidase cofactor, TGF-beta1 modulation
- Days 14–180+ (remodeling phase)
- Increases type I:III collagen ratio (50% more type I, 35% less type III)
- Minor vascular effect; primarily structural
- In vitro human fibroblast studies; wound healing clinical trials
- Bottom Line
- Each peptide targets a distinct phase and mechanism—BPC-157 for inflammation and vascularization, TB-500 for cell recruitment, GHK-Cu for collagen quality and crosslinking. Combining all three addresses the full healing timeline rather than a single pathway.
- Stack synergy is logical based on mechanism but lacks randomized controlled human trials specific to ACL injuries.